KREBSBIO61.00

Krebs Biochemicals and Industries Limited

· Pharma & Health
₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹132 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt193.4212.2224.8224.8
Net Debt193.3212.1224.7224.7
Total Debt/Equity-1.62-1.45-1.38-1.38
Net Debt/Equity-1.62-1.45-1.38-1.38
Total Debt/EBITDA-22.17-14.12-41.25-41.25
Net Debt/EBITDA-22.16-14.11-41.23-88.60
Interest Coverage (EBIT/Interest)-3.30-3.67-1.68-1.68
Total Debt/Total Capital %260.64321.68362.15362.15
As Filed — company-reported covenants
Debt/Equity (as filed)-2.00-1.45-1.38
Debt Service Coverage (as filed)-0.07-0.01
Interest Service Coverage (as filed)-3.00-3.55-1.39
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.